Huolingshengji Granules ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04950933 (ClinicalTrials.gov) | June 1, 2020 | 27/6/2021 | The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules | A Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase ? Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome) | Amyotrophic Lateral Sclerosis | Drug: Huolingshengji Granules;Drug: Riluzole tablet | Peking University Third Hospital | The Second Hospital of Hebei Medical University | Recruiting | 45 Years | 70 Years | All | 144 | Phase 2/Phase 3 | China |